網易-S(09999.HK)升逾5% 獲內地批准新遊戲版號
網易-S(09999.HK)今日(28日)高開3.85%後升幅擴大,最高見178.8元。現報178元,升5.33%,成交84.49萬股,涉資1.49億元。網易ADR(NTES.US)隔夜股價彈5.3%至113.14美元。
國家新聞出版署公布2月份國產網絡遊戲審批信息,共111款遊戲獲批版號,當中包括網易旗下《天啟行動》。另外,網易將於明日(29日)公布季績,本網綜合6間券商預測,網易2023年第四季非公認會計準則下(non-GAAP)歸屬於公司股東的持續經營淨利潤介乎69.45億至81.47億元人民幣,較2022年同期的48億人民幣,按年增長44.3%至69.3%,中位數76.24億人民幣按年升近58%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.